Hello, have you checked the known short positions?
Ellison has been taking advantage of the shorts.
Some of the short hedges have also been shorting IPGroup[IPO] possibly because of their 10% exposure to ONT. It's pretty obvious that ONT's research income is going to fall thanks to Trump.
What will replace that income? It has to be clinical and industrial sectors.
Sanghera has gone on record to say that 2025 is the start of clinical income, and NHS placements are rapidly increasing. It's impossible to say how quickly these other income segments will make a meaningful contribution.
Thanks for the comment Phil. I hadn't checked the short interest until you mentioned it and I see that it emerged in December. I agree it is obvious that research income is going to suffer under Trump as was confirmed by ONT upon announcing 2024 results.
However, in the 2024 results presentation management said that research revenue in the US was underrepresented versus the rest of the group if I recall correctly. I think the 10-15% they've stripped out of guidance covers all revenue currently derived from NIH funding so it seems like this risk is now priced in?
They are very confident on non-research markets and saw strong double digit percentage growth in this part of the business in 2024. The likes of the Plasmidsaurus partnership and the Guy's and St Thomas' project rolling out across 30 NHS trusts gives management confidence in guiding >30% growth in non-research in 2025. It's worth listening to the results presentation to understand further.
Hello, have you checked the known short positions?
Ellison has been taking advantage of the shorts.
Some of the short hedges have also been shorting IPGroup[IPO] possibly because of their 10% exposure to ONT. It's pretty obvious that ONT's research income is going to fall thanks to Trump.
What will replace that income? It has to be clinical and industrial sectors.
Sanghera has gone on record to say that 2025 is the start of clinical income, and NHS placements are rapidly increasing. It's impossible to say how quickly these other income segments will make a meaningful contribution.
Thanks for the comment Phil. I hadn't checked the short interest until you mentioned it and I see that it emerged in December. I agree it is obvious that research income is going to suffer under Trump as was confirmed by ONT upon announcing 2024 results.
https://x.com/BrazierMat68791/status/1890010717669179492
However, in the 2024 results presentation management said that research revenue in the US was underrepresented versus the rest of the group if I recall correctly. I think the 10-15% they've stripped out of guidance covers all revenue currently derived from NIH funding so it seems like this risk is now priced in?
They are very confident on non-research markets and saw strong double digit percentage growth in this part of the business in 2024. The likes of the Plasmidsaurus partnership and the Guy's and St Thomas' project rolling out across 30 NHS trusts gives management confidence in guiding >30% growth in non-research in 2025. It's worth listening to the results presentation to understand further.
https://stream.brrmedia.co.uk/broadcast/6781466d05217c8a87d3b0ac/67c6ae0c037e06eebebbebf6